Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 10 studies | 21% ± 5% | |
pericyte | 8 studies | 20% ± 3% | |
endothelial cell | 6 studies | 26% ± 8% | |
smooth muscle cell | 6 studies | 18% ± 2% | |
endothelial cell of vascular tree | 6 studies | 19% ± 3% | |
epithelial cell | 5 studies | 39% ± 20% | |
non-classical monocyte | 4 studies | 25% ± 7% | |
B cell | 4 studies | 22% ± 2% | |
CD4-positive, alpha-beta T cell | 4 studies | 20% ± 5% | |
natural killer cell | 4 studies | 18% ± 2% | |
mast cell | 4 studies | 19% ± 3% | |
classical monocyte | 3 studies | 23% ± 5% | |
connective tissue cell | 3 studies | 21% ± 2% | |
basal cell | 3 studies | 26% ± 12% | |
CD8-positive, alpha-beta T cell | 3 studies | 17% ± 2% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1383.27 | 1445 / 1445 | 100% | 9.00 | 183 / 183 |
ovary | 100% | 1832.99 | 180 / 180 | 100% | 12.64 | 430 / 430 |
lung | 100% | 1636.77 | 578 / 578 | 100% | 10.32 | 1154 / 1155 |
uterus | 100% | 1630.89 | 170 / 170 | 99% | 8.75 | 456 / 459 |
stomach | 100% | 1192.87 | 359 / 359 | 99% | 9.67 | 284 / 286 |
intestine | 100% | 1543.46 | 966 / 966 | 99% | 10.35 | 522 / 527 |
breast | 100% | 1762.96 | 459 / 459 | 99% | 8.04 | 1107 / 1118 |
thymus | 100% | 1319.84 | 653 / 653 | 99% | 9.16 | 599 / 605 |
bladder | 100% | 1499.81 | 21 / 21 | 99% | 8.70 | 498 / 504 |
prostate | 100% | 1401.85 | 245 / 245 | 99% | 9.67 | 496 / 502 |
kidney | 100% | 1140.13 | 89 / 89 | 98% | 8.71 | 883 / 901 |
pancreas | 99% | 768.31 | 324 / 328 | 99% | 8.87 | 176 / 178 |
brain | 98% | 570.81 | 2584 / 2642 | 99% | 7.89 | 699 / 705 |
liver | 100% | 1096.12 | 226 / 226 | 95% | 5.09 | 387 / 406 |
skin | 100% | 1646.85 | 1809 / 1809 | 86% | 5.07 | 406 / 472 |
adrenal gland | 100% | 1114.72 | 258 / 258 | 86% | 3.49 | 197 / 230 |
blood vessel | 100% | 1698.56 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 8.10 | 29 / 29 |
spleen | 100% | 1426.72 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 5.83 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.49 | 1 / 1 |
adipose | 100% | 1909.98 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 99% | 779.00 | 796 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 829.52 | 851 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 974.82 | 870 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 76% | 3.38 | 61 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0051321 | Biological process | meiotic cell cycle |
GO_0016076 | Biological process | snRNA catabolic process |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0017069 | Molecular function | snRNA binding |
GO_0071889 | Molecular function | 14-3-3 protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0003727 | Molecular function | single-stranded RNA binding |
GO_0097157 | Molecular function | pre-mRNA intronic binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | RBM7 |
Protein name | RNA-binding protein 7 (RNA-binding motif protein 7) RNA binding motif protein 7 |
Synonyms | hCG_2032547 |
Description | FUNCTION: RNA-binding subunit of the trimeric nuclear exosome targeting (NEXT) complex, a complex that functions as an RNA exosome cofactor that directs a subset of non-coding short-lived RNAs for exosomal degradation . NEXT is involved in surveillance and turnover of aberrant transcripts and non-coding RNAs . Binds preferentially polyuridine sequences and associates with newly synthesized RNAs, including pre-mRNAs and short-lived exosome substrates such as promoter upstream transcripts (PROMPTs), enhancer RNAs (eRNAs), and 3'-extended products from small nuclear RNAs (snRNAs) . Participates in several biological processes including DNA damage response (DDR) and stress response . During stress response, activation of the p38MAPK-MK2 pathway decreases RBM7-RNA-binding and subsequently the RNA exosome degradation activities, thereby modulating the turnover of non-coding transcriptome . Participates in DNA damage response (DDR), through its interaction with MEPCE and LARP7, the core subunits of 7SK snRNP complex, that release the positive transcription elongation factor b (P-TEFb) complex from the 7SK snRNP. In turn, activation of P-TEFb complex induces the transcription of P-TEFb-dependent DDR genes to promote cell viability . . |
Accessions | F5H674 J3KPD3 ENST00000375490.10 ENST00000544313.5 G3V1T9 ENST00000540163.5 F5GXV8 Q9Y580 ENST00000542140.5 F5GY08 F5H606 Q6IRX3 ENST00000544582.1 ENST00000545678.1 ENST00000541475.5 |